Detalhe da pesquisa
1.
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Cancer Invest
; 31(3): 172-6, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23406188